Search alternatives:
significant severity » significant diversity (Expand Search), significant benefits (Expand Search), significant event (Expand Search)
point decrease » point increase (Expand Search)
Showing 1 - 20 results of 32,439 for search '(( significant severity based ) OR ( significant ((amount decrease) OR (point decrease)) ))', query time: 1.01s Refine Results
  1. 1
    Pitfalls of merging only considering end-points.

    Pitfalls of merging only considering end-points. by Almiqdad Elzein (13141038)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  2. 2
    Maximum IFN concentrations are decreased in severe patients.

    Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

    Published 2025
    “…B) Model predictions of mean values of maximal IFN concentrations in mild and severe virtual patients. Statistical differences in maximal IFN values between groups are marked by a level of significance (*) estimated based on p-values above the box plots (*, p < 0.05; **, p < 0.005; ***, p < 0.0005; ****, p < 5e-5). …”
    Save to List
    Saved in:
  3. 3
    Nielsen scanner data trend in discount amount for unsweetened beverages.

    Nielsen scanner data trend in discount amount for unsweetened beverages. by Osama M. El-Sayed (11920046)

    Published 2023
    Save to List
    Saved in:
  4. 4
    Pro- and anti-inflammatory cytokines are significantly decreased at acute time points following IR.

    Pro- and anti-inflammatory cytokines are significantly decreased at acute time points following IR. by Jordan A. Gunning (18143970)

    Published 2024
    Save to List
    Saved in:
  5. 5
    Nielsen scanner data trend in discount amount for noncalorically sweetened beverages.

    Nielsen scanner data trend in discount amount for noncalorically sweetened beverages. by Osama M. El-Sayed (11920046)

    Published 2023
    Save to List
    Saved in:
  6. 6
    Nielsen scanner data trend in discount amount for sugar-sweetened beverages.

    Nielsen scanner data trend in discount amount for sugar-sweetened beverages. by Osama M. El-Sayed (11920046)

    Published 2023
    Save to List
    Saved in:
  7. 7
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Significant differences between Th17-cell levels of dogs suffering from IVDH at all three sampling time points and in comparison with the healthy control group.

    Significant differences between Th17-cell levels of dogs suffering from IVDH at all three sampling time points and in comparison with the healthy control group. by Annika Kämpe (11507012)

    Published 2021
    Subjects:
    Save to List
    Saved in:

Search Tools: